%PDF-1.4
1 0 obj
<< /Type /Catalog /Pages 2 0 R >>
endobj
2 0 obj
<< /Type /Pages /Kids [ 4 0 R 6 0 R 8 0 R 10 0 R 12 0 R 14 0 R ] /Count 6 >>
endobj
3 0 obj
<< /Length 5083 >>
stream
BT
/F1 10 Tf
72 720 Td
(Exhibit 10.2   INTELLECTUAL PROPERTY AGREEMENT   This Intellectual Property Agreement) Tj
0 -12 Td
(\(this "Agreement"\) is entered into on May 12, 2020 \("Effective Date"\), concerning the) Tj
0 -12 Td
(pursuits set forth herein for the collective development, implementation and) Tj
0 -12 Td
(commercialization of a potential treatment for the COVID-19 virus and its effects on the) Tj
0 -12 Td
(human body \(collectively referred to herein as the "Joint Venture"\) by and between:   Marv) Tj
0 -12 Td
(Enterprises, LLC, a Limited Liability Company organized under the laws of the Commonwealth) Tj
0 -12 Td
(of Pennsylvania \("Marv"\),   Premier Biomedical, Inc. \(OTC Pink: BIEI\), a Nevada) Tj
0 -12 Td
(corporation \("Premier"\),   Technology Health, Inc. \(OTC Pink: HALB\), a Colorado) Tj
0 -12 Td
(corporation f/k/a Halberd Corporation \("THI"\),   Each shall be referred to as a "Party") Tj
0 -12 Td
(and collectively as the "Parties."   RECITALS:               WHEREAS, Marv is a single) Tj
0 -12 Td
(member LLC with Dr. Mitchell Felder as the sole member.   WHEREAS, Premier is publicly) Tj
0 -12 Td
(traded on the Pink Sheets, trading symbol BIEI.   WHEREAS, THI is publicly traded on the) Tj
0 -12 Td
(Pink Sheets, trading symbol HALB.   WHEREAS, Marv is owner of U.S. Patent 9,216,386 and) Tj
0 -12 Td
(U.S. Patent 8,758,287 collectively referred to as the "Issued Patents".   WHEREAS, Premier) Tj
0 -12 Td
(has an Exclusive License to the Issued Patents via an Agreement executed by Marv and) Tj
0 -12 Td
(Premier on May 12, 2010 \("2010 Agreement"\).   WHEREAS, Marv has subsequently filed) Tj
0 -12 Td
(numerous patent applications on subject matter related to the Issued Patents which are) Tj
0 -12 Td
(listed in Appendix A.   WHEREAS, Marv and Premier expanded Premier's Exclusive License to) Tj
0 -12 Td
(include all the Applications listed in Appendix A via a Third Addendum to the 2010) Tj
0 -12 Td
(Agreement executed by Marv and Premier on the Effective Date \("2020 Agreement"\).) Tj
0 -12 Td
(WHEREAS, Marv has filed US provisional patent applications specifically related to methods) Tj
0 -12 Td
(of treatment for Covid-19 as starred in Appendix A \(Covid-19 Applications\) to which) Tj
0 -12 Td
(Premier has an exclusive license via the 2020 Agreement.   WHEREAS, this Agreement) Tj
0 -12 Td
(contemplates the development of a methodology for the extracorporeal treatment of a) Tj
0 -12 Td
(patient's body fluid to treat Covid-19 \(Field of Covid-19 Treatment\).   WHEREAS, the) Tj
0 -12 Td
(Parties are desirous of collaborating for the creation and distribution of products) Tj
0 -12 Td
(designed in the Field of Covid-19 Treatment \(Covid-19 Licensed Products\)   WHEREAS, THI is) Tj
0 -12 Td
(desirous of exclusively licensing the Applications listed in Appendix A;   WHEREAS,) Tj
0 -12 Td
(Premier is willing to assign its rights in the 2010 Agreement/2020 Agreement;   WHEREAS,) Tj
0 -12 Td
(Marv in this Agreement gives its written consent for Premier to assign its rights in the) Tj
0 -12 Td
(2010 Agreement/2020 Agreement to THI;                NOW, THEREFORE, for good and adequate) Tj
0 -12 Td
(consideration, the receipt of which is hereby acknowledged, the Parties covenant, promise) Tj
0 -12 Td
(and agree as follows:     1) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(AGREEMENT   1.         RECITALS. The Recitals are hereby incorporated herein by this) Tj
0 -12 Td
(reference, as if fully restated herein.   2.      LICENSING. To the extent that terms in) Tj
0 -12 Td
(the 2010 Agreement/2020 Agreement are not contradicted or revised here, the terms as) Tj
0 -12 Td
(stated in 2010 Agreement/2020 Agreement remain in full effect, are controlling, and apply) Tj
0 -12 Td
(to THI licensing of the Applications in Appendix A and the Licensed Products derived) Tj
0 -12 Td
(therefrom.   \(a\) License - THI is granted the following rights to the Applications in) Tj
0 -12 Td
(Appendix A and the Licensed Products derived therefrom:   Scope. The licenses granted) Tj
0 -12 Td
(herein are exclusive worldwide licenses to:   1.         make, have made, use, lease, sell) Tj
0 -12 Td
(and import Licensed Products for the legal purposes of researching, developing,) Tj
0 -12 Td
(manufacturing, assembling, distributing, and selling the Licensed Products;   2.) Tj
0 -12 Td
(make, have made, use and import machines, tools, materials and other instrumentalities,) Tj
0 -12 Td
(insofar as such machines, tools, materials and other instrumentalities are involved in or) Tj
0 -12 Td
(incidental to the research, development, manufacture, testing or repair of Licensed) Tj
0 -12 Td
(Products which are or have been made, used, leased, owned, sold or imported by the) Tj
0 -12 Td
(Licensee; and   3.         convey to any customer of the Licensee, with respect to any) Tj
0 -12 Td
(Licensed Product which is sold or leased to such customer, rights to use and resell such) Tj
0 -12 Td
(Licensed Product as sold or leased by Licensee \(whether or not as part of a larger) Tj
0 -12 Td
ET
endstream
endobj
4 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 15 0 R >> >> /Contents 3 0 R >>
endobj
5 0 obj
<< /Length 5239 >>
stream
BT
/F1 10 Tf
72 720 Td
(combination\); provided, however, that no rights may be conveyed to customers with respect) Tj
0 -12 Td
(to any Invention which is directed to \(i\) a combination of such Licensed Product \(as sold) Tj
0 -12 Td
(or leased\) with any other product, \(ii\) a method or process which is other than the) Tj
0 -12 Td
(inherent use of such Licensed Product itself \(as sold or leased\), or \(iii\) a method or) Tj
0 -12 Td
(process involving the use of a Licensed Product to manufacture \(including associated) Tj
0 -12 Td
(testing\) any other product.   4.         Licenses granted herein are solely for products) Tj
0 -12 Td
(in the form sold by the Licensee and are not to be construed either \(i\) as consent by the) Tj
0 -12 Td
(Marv to any act which may be performed by the Licensee, except to the extent impacted by a) Tj
0 -12 Td
(patent licensed herein to the Licensee, or \(ii\) to include licenses to contributorily) Tj
0 -12 Td
(infringe or induce infringement under U.S. law or a foreign equivalent thereof.   5. The) Tj
0 -12 Td
(grant of each license hereunder includes the right to grant sublicenses to Related) Tj
0 -12 Td
(Companies for so long as it remains a Related Companies. Any such sublicense may be made) Tj
0 -12 Td
(effective retroactively, but not prior to the effective date hereof, nor prior to the) Tj
0 -12 Td
(sublicensee's becoming a Related Company.              \(b\)      Reports and Payments - For) Tj
0 -12 Td
(the above exclusive licensing rights, THI will pay for various costs associated with this) Tj
0 -12 Td
(Agreement. The costs listed below are to be hereinafter referred to as the "License Fee",) Tj
0 -12 Td
(to be paid by and through THI. The use of the License Fee is further broken down below:) Tj
0 -12 Td
(1. $20,000, payable to Marv Enterprises, LLC or as it directs, which has already been paid) Tj
0 -12 Td
(into the account of Marv Enterprises, LLC at the Lynch Law Group   2. The total sum of) Tj
0 -12 Td
(non-paid invoices \(estimated to be approximately $80,000\) payable to Marv Enterprises,) Tj
0 -12 Td
(LLC, previously owed by Premier to Marv up until the effective date of this Agreement,) Tj
0 -12 Td
(payable in total by no later than July 20, 2020.   3. Reports.       a . Within thirty) Tj
0 -12 Td
(\(30\) days after the end of each quarterly period ending on March                 31st,) Tj
0 -12 Td
(June 30th, September 30th, or December 31st, commencing with the one-year anniversary of) Tj
0 -12 Td
(the effective date of this Agreement, THI shall furnish to Marv a statement certified by a) Tj
0 -12 Td
(responsible official of the Licensee showing in a manner acceptable to Marv:   i. all) Tj
0 -12 Td
(Licensed Products which were sold, leased or put into use during such quarterly period by) Tj
0 -12 Td
(THI or any of its Related Companies, the gross sales received for the Licensed Products,) Tj
0 -12 Td
(and the Fair Market Values of such Licensed Products;   ii. all services performed by THI) Tj
0 -12 Td
(or any of its Related Companies that directly or indirectly used Licensed Product, the) Tj
0 -12 Td
(gross sales received by the services, and the Fair Market Value of such services;     2) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(iii. the amount of royalty payable thereon, and   iv. if no Licensed Product has been so) Tj
0 -12 Td
(sold, leased or put into use or if no services have been performed, the statement shall) Tj
0 -12 Td
(show that fact.    b. Within such thirty \(30\) days, THI shall pay in United States dollars) Tj
0 -12 Td
(to Marv at PO Box 1332, Hermitage, PA 16148, or other address provided by Marv, the) Tj
0 -12 Td
(royalties payable in accordance with such statement. Any conversion to United States) Tj
0 -12 Td
(dollars shall be at the prevailing rate for bank cable transfers as quoted for the last) Tj
0 -12 Td
(day of such quarterly period by leading United States banks in New York City dealing in) Tj
0 -12 Td
(the foreign exchange market.   c. Overdue payments hereunder shall be subject to a late) Tj
0 -12 Td
(payment charge calculated at an annual rate of three percent \(3%\) over the prime rate or) Tj
0 -12 Td
(successive prime rates \(as posted in New York City\) during delinquency. If the amount of) Tj
0 -12 Td
(such charge exceeds the maximum permitted by law, such charge shall be reduced to such) Tj
0 -12 Td
(maximum.   \(c\) THI further agrees to pay Intellectual Property Prosecution and Costs) Tj
0 -12 Td
(Applications in Appendix A directly to Marv.   1. Costs. THI shall reimburse Marv for all) Tj
0 -12 Td
(IP Costs incurred on behalf of THI, as well as pre-paid IP Costs incurred prior to the) Tj
0 -12 Td
(Effective Date of this Agreement, including the costs of provisional and non-provisional) Tj
0 -12 Td
(applications that are filed to preserve Intellectual Property. Reimbursement for pre-paid) Tj
0 -12 Td
(IP Costs shall be in accordance with 2 \(b\) 2 above.    2. Extension of Application. By) Tj
0 -12 Td
(written notice to Marv and at least ninety \(90\) days before the non-extendable due date) Tj
0 -12 Td
(for the filing of a national phase application of an Application, THI shall elect those) Tj
0 -12 Td
ET
endstream
endobj
6 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 15 0 R >> >> /Contents 5 0 R >>
endobj
7 0 obj
<< /Length 5203 >>
stream
BT
/F1 10 Tf
72 720 Td
(countries or authorities in which it desires to file a patent application based on the) Tj
0 -12 Td
(Application. Intellectual Property rights in an unelected country shall revert to Marv.) Tj
0 -12 Td
(3. Notice to Licensee. Before payment of any IP Cost, Marv shall notify THI for a time) Tj
0 -12 Td
(period being the lesser of \(i\) at least sixty \(60\) days before the IP Cost is due or \(ii\)) Tj
0 -12 Td
(as soon as is practicable after receiving knowledge of the IP Cost. The notice will) Tj
0 -12 Td
(identify \(i\) the Application or Patent, \(ii\) the country, \(iii\) the reason for the IP) Tj
0 -12 Td
(Cost, and \(iv\) the Due Date for payment. THI shall then affirm or deny payment.) Tj
0 -12 Td
(Affirmation of payment must be received by Marv within fourteen \(14\) days of the mailing) Tj
0 -12 Td
(date of the notice or the THI shall be deemed to have denied payment.   a. If THI affirms) Tj
0 -12 Td
(a payment, THI shall reimburse Marv for all IP Costs arising from the payment and shall) Tj
0 -12 Td
(then retain its license for the Application or Patent in that country.   b. If THI denies) Tj
0 -12 Td
(payment, THI shall have no obligation to pay IP Costs associated with the Application or) Tj
0 -12 Td
(Patent in that country, but the license and all associated rights for that Application or) Tj
0 -12 Td
(Patent shall revert to Marv.   4. Reimbursement by Licensee. THI shall prepay Marv for any) Tj
0 -12 Td
(affirmed IP Cost before payment is to be made by Marv. Marv shall have no duty to pay an) Tj
0 -12 Td
(IP Cost, whether affirmed or not affirmed, for which Marv does not receive prepayment. If) Tj
0 -12 Td
(THI does not pay Marv by the Due Date, the Application or Patent shall revert to Marv as) Tj
0 -12 Td
(if THI had denied payment under section 2\(c\)3.     5. Reversion of License. If a reversion) Tj
0 -12 Td
(occurs under this Article, the license in that country in which reversion has occurred) Tj
0 -12 Td
(will be terminated, and THI shall have no further right in the Application or Patent for) Tj
0 -12 Td
(that country. The right shall revert to Marv who will then have the right to pursue) Tj
0 -12 Td
(protection for the reverted Application or Patent. Marv has no further duty to THI for a) Tj
0 -12 Td
(reverted Application or Patent.   6. Applications. Defines as all applications of the) Tj
0 -12 Td
(United States and foreign countries, including Patent Cooperation Treaty applications that) Tj
0 -12 Td
(claim priority to the Applications listed in Appendix A, including any non-provisional) Tj
0 -12 Td
(applications, continuations, continuations-in-part, divisions, reissues, re-examinations) Tj
0 -12 Td
(or extensions thereof; and all applications including those applications filed in the) Tj
0 -12 Td
(United States or applications filed under the Patent Cooperation Treaty on subject matter) Tj
0 -12 Td
(directly related to the Applications in Appendix A whether or not priority to said) Tj
0 -12 Td
(applications was claimed.    \(d\)  Royalty Payments.   1. Royalty payments are payable from) Tj
0 -12 Td
(THI to Marv Enterprises, LLC and will be in the amount of 5% of the Fair Market Value of:) Tj
0 -12 Td
(a. Licensed Product that is sold, leased or put into use by the THI or any Related) Tj
0 -12 Td
(Companies in the preceding calendar quarter; and   b. any service performed by THI or any) Tj
0 -12 Td
(Related Companies that directly or indirectly uses Licensed Product.     3) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(2. This License does not include a minimum annual royalty payable by THI to Marv.   3.) Tj
0 -12 Td
(Fair Market Value" means, with respect to any Licensed Product sold, leased or put into) Tj
0 -12 Td
(use, the Selling Price actually obtained in an arm's length transaction for a product) Tj
0 -12 Td
(comprising a Licensed Product in the form in which the product is sold, whether or not) Tj
0 -12 Td
(assembled and without excluding any components or subassemblies thereof which are included) Tj
0 -12 Td
(in such Selling Price.   "Selling price" shall exclude: usual trade discounts actually) Tj
0 -12 Td
(allowed to unaffiliated persons or entities such as packing costs, costs of transportation) Tj
0 -12 Td
(and transportation insurance, and import, export, excise, sales and value added taxes, and) Tj
0 -12 Td
(custom duties.   4. In addition to the 5% amount calculated pursuant to the preceding) Tj
0 -12 Td
(paragraph, there shall be an identical 5% amount to be paid from THI, per Premier's) Tj
0 -12 Td
(consideration, to certain shareholders of Premier, as identified by Premier, as of a) Tj
0 -12 Td
(record date to be determined in the future, on an annual basis, commencing on the one-year) Tj
0 -12 Td
(anniversary of this Agreement until a total amount of $40,000,000 has been paid to) Tj
0 -12 Td
(Premier. This royalty is separate and distinct from the royalty obligation to Marv as) Tj
0 -12 Td
(stated in 2\(d\)1.            \(e\)     If THI does not make the obligatory payments as stated) Tj
0 -12 Td
(in 2\(b\) by the dates stated, the Exclusive License will revert back to Premier.   3.) Tj
0 -12 Td
ET
endstream
endobj
8 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 15 0 R >> >> /Contents 7 0 R >>
endobj
9 0 obj
<< /Length 5122 >>
stream
BT
/F1 10 Tf
72 720 Td
(JOINT VENTURE   \(a\)   Premier and THI will jointly cooperate in developing Covid-19) Tj
0 -12 Td
(Licensed Products, to be memorialized by them in a Technology Acquisition and Financing) Tj
0 -12 Td
(Agreement. For the joint venture the following payments will be made by and through THI:) Tj
0 -12 Td
(1. $750,000, payable to THI  in total by no later than June 20 , 2020. The payment will be) Tj
0 -12 Td
(for developing fluorescently-conjugated antibodies in the Field of Covid-19 Treatments.) Tj
0 -12 Td
(2.    $1,150,000, payable to THI  in total by no later than July 30, 2020.     The payment) Tj
0 -12 Td
(will be for development of laser technology in the Field of Covid-19 Treatments.   3.) Tj
0 -12 Td
($500,000 payable to a subsidiary of THI to be formed in the United Kingdom, for research) Tj
0 -12 Td
(and development to be performed in the United Kingdom, by and at the direction of Mohammed) Tj
0 -12 Td
(Zulfiquar and/or Datatechnics Inc. as invoiced by Mohammed Zulfiquar and/or Datatechnics) Tj
0 -12 Td
(Inc., for expenses and at an hourly rate to Mohammed Zulfiquar and his designees.   \(b\).) Tj
0 -12 Td
(Premier may partner with other organizations as needed to effectuate the development of) Tj
0 -12 Td
(technology in the Field of Covid-19 Treatments.   \(c\) Marv will have no direct role in the) Tj
0 -12 Td
(development of technology in the Field of Covid-19 Treatment or in the Joint Venture.) Tj
0 -12 Td
(Marv, through its sole member Dr. Mitchell Felder, may from time to time be consulted) Tj
0 -12 Td
(regarding the development of technology in the Field of Covid-19 Treatment. This) Tj
0 -12 Td
(consultation will be done solely at Marv's discretion.   \(d\)   Premier and THI may execute) Tj
0 -12 Td
(separate agreements further outlining the conditions of the Joint Venture to effectuate) Tj
0 -12 Td
(the development of technology in the Field of Covid-19 Treatment.   \(e\)     If THI does) Tj
0 -12 Td
(not make the obligatory payments as stated in 3\(a\) by the dates stated, the Exclusive) Tj
0 -12 Td
(License will revert back to Premier, provided, however, that in such event, THI would) Tj
0 -12 Td
(still be entitled to a proportionate interest in any Covid-19 Licensed Products, such) Tj
0 -12 Td
(portion being equal to a fraction, the numerator of which shall be the actual amount paid) Tj
0 -12 Td
(and the denominator of which shall be $2,000,000.   4.        NO BROKERAGE FEE. Each Party) Tj
0 -12 Td
(hereby represents and warrants that there has been no agreement which might cause any) Tj
0 -12 Td
(other person to become entitled to a finder's fee, a broker's fee or a commission as a) Tj
0 -12 Td
(result of the transactions contemplated hereunder.   5.  REQUIREMENT. The Parties agree) Tj
0 -12 Td
(that Marv and/or Mitchell S. Felder shall have no obligation and/or involvement in any) Tj
0 -12 Td
(capital raising activities for THI or Premier at any time and for any reason. Further, the) Tj
0 -12 Td
(150,000,000 \(one hundred and fifty million\) stock warrants previously ceded to Mitchell S.) Tj
0 -12 Td
(Felder by Halberd/THI shall not be eliminated, cancelled, or altered in any way, and for) Tj
0 -12 Td
(any reason, unless specifically directed at the request of Mitchell S. Felder.   6.) Tj
0 -12 Td
(NONEXCLUSIVE ENGAGEMENT; EXTENT OF SERVICES. The Parties agree that the relationship) Tj
0 -12 Td
(contemplated by this Agreement is a nonexclusive engagement/venture and that each Party) Tj
0 -12 Td
(now renders and may continue to render consulting services and/or sell or provide products) Tj
0 -12 Td
(to other companies that may or may not conduct activities similar to those of each other) Tj
0 -12 Td
(Party.     4) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(7.        CONFIDENTIALITY.   Each Party agrees to hold in confidence confidential) Tj
0 -12 Td
(information acquired in the course of this relationship with the other Parties and their) Tj
0 -12 Td
(associates. Each Party agrees to refrain from, either during period of this Agreement or) Tj
0 -12 Td
(at any other time thereafter, disclosing, using or disseminating such confidential) Tj
0 -12 Td
(information, for its or another's benefit, in any way acquired in the course of any) Tj
0 -12 Td
(association arising out of this Agreement. For purposes of this Agreement, confidential) Tj
0 -12 Td
(information shall include contacts and introductions to third parties and information) Tj
0 -12 Td
(relating thereto. Confidential information, knowledge or data of a Party and/or its) Tj
0 -12 Td
(affiliates shall not include any information which is or becomes generally available to) Tj
0 -12 Td
(the public other than as a result of a disclosure by such Party or its representatives.) Tj
0 -12 Td
(Confidential information should further include:   all information \(in whatever form and) Tj
0 -12 Td
(whether or not marked or otherwise identified as confidential\), including financial) Tj
0 -12 Td
(statements, business plans or records, concepts, marketing studies, projections, sales or) Tj
0 -12 Td
ET
endstream
endobj
10 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 15 0 R >> >> /Contents 9 0 R >>
endobj
11 0 obj
<< /Length 5615 >>
stream
BT
/F1 10 Tf
72 720 Td
(pricing information, customer or supplier information, agreements with third parties,) Tj
0 -12 Td
(Intellectual Property \(as defined below\) or other data provided by or on behalf of the) Tj
0 -12 Td
(Disclosing Party to the Recipient and \(ii\) all notes, analyses, compilations, studies,) Tj
0 -12 Td
(interpretations or other material prepared by the Recipient or its Representatives which) Tj
0 -12 Td
(contain or reflect or are based upon, in whole or in part, information furnished by the) Tj
0 -12 Td
(Disclosing Party pursuant to this Agreement. "Confidential Information" does not include) Tj
0 -12 Td
(information which \(a\) is obtained by the Recipient from a third party who is not known to) Tj
0 -12 Td
(Recipient to be prohibited from transmitting such information to the Recipient, or \(b\) was) Tj
0 -12 Td
(already in the Recipient's possession prior to its entry into this Agreement and which is) Tj
0 -12 Td
(not subject to any restrictions which would prohibit its disclosure to the Recipient in) Tj
0 -12 Td
(connection with the parties' evaluation of the Transaction or \(c\) is or becomes generally) Tj
0 -12 Td
(available to the public other than as a result of a breach of any confidentiality) Tj
0 -12 Td
(restrictions to the Recipient.   "Intellectual Property" shall mean any Confidential) Tj
0 -12 Td
(Information proprietary to the Disclosing Party and any trademark, service mark, trade) Tj
0 -12 Td
(name, invention, improvement, discovery, patent, patent application, trade secret,) Tj
0 -12 Td
(copyright, copyrightable work, trade dress, mask work, computer program or any other type) Tj
0 -12 Td
(of proprietary intellectual property to which the Disclosing party claims any rights,) Tj
0 -12 Td
(including any registrations or applications for registration or renewals of any of the) Tj
0 -12 Td
(foregoing, and all copies and tangible embodiments of the foregoing in whatever form or) Tj
0 -12 Td
(medium. Confidential information shall also mean any information not generally made) Tj
0 -12 Td
(available or known to the public and shall include, without limitation, all ideas,) Tj
0 -12 Td
(inventions, software, documentation, flowcharts, diagrams, improvements, discoveries,) Tj
0 -12 Td
(research and development, know how, formulas, compositions, manufacturing and production) Tj
0 -12 Td
(processes and techniques, technical data, designs, drawings, plans, specifications, and) Tj
0 -12 Td
(all other information or material within the definition of a "trade secret" as set forth) Tj
0 -12 Td
(in the Uniform Trade Secret Act, or which either party otherwise reasonably considers) Tj
0 -12 Td
(proprietary.   Copies; Return of Confidential Information. The parties may copy or) Tj
0 -12 Td
(otherwise reproduce any written Confidential Information; provided, however, that all such) Tj
0 -12 Td
(Confidential Information and copies thereof shall be promptly returned to the Disclosing) Tj
0 -12 Td
(Party or, at the option of the Disclosing Party, destroyed, upon the Disclosing Party's) Tj
0 -12 Td
(request, such destruction to be certified in writing.   8.           VENUE. This Agreement) Tj
0 -12 Td
(and the rights of the Parties hereunder shall be governed by and construed in accordance) Tj
0 -12 Td
(with the laws of the Commonwealth of Pennsylvania including all matters of construction,) Tj
0 -12 Td
(validity, performance, and enforcement and without giving effect to the principles of) Tj
0 -12 Td
(conflict of laws. Venue for any action brought under this Agreement shall be in the) Tj
0 -12 Td
(appropriate court in Mercer County, Pennsylvania.     9.       MATERIALITY. The Parties) Tj
0 -12 Td
(agree and stipulate that each and every term and condition contained in this Agreement is) Tj
0 -12 Td
(material, and that each and every term and condition may be reasonably accomplished within) Tj
0 -12 Td
(the time limitations, and in the manner set forth in this Agreement. The Parties agree and) Tj
0 -12 Td
(stipulate that time is of the essence with respect to compliance with each and every item) Tj
0 -12 Td
(set forth in this Agreement.   10.        AMENDMENTS/BINDING. This Agreement may not be) Tj
0 -12 Td
(amended or modified except by written agreement subscribed by all of the Parties to be) Tj
0 -12 Td
(charged with such modification. This Agreement shall be binding upon and shall inure to) Tj
0 -12 Td
(the benefit of the Parties hereto and their respective partners, employees, agents,) Tj
0 -12 Td
(servants, heirs, administrators, executors, successors, representatives and assigns.   11.) Tj
0 -12 Td
(ENTIRE AGREEMENT. This Agreement, along with the exhibits hereto, sets forth the entire) Tj
0 -12 Td
(agreement and understanding of the Parties hereto and supersedes any and all prior) Tj
0 -12 Td
(arrangements and understandings related to the subject matter hereof except for as) Tj
0 -12 Td
(specifically stated in this  Agreement with regards to the 2010 Agreement and the 2020) Tj
0 -12 Td
(Agreement and  licensing rights. No understanding, promise, inducement, statement of) Tj
0 -12 Td
(intention, representation, warranty, covenant or condition, written or oral, express or) Tj
0 -12 Td
(implied, whether by statute or otherwise, has been made by any Party hereto which is not) Tj
0 -12 Td
(embodied in this Agreement or the written statements, certificates, or other documents) Tj
0 -12 Td
(delivered pursuant hereto or in connection with the transactions contemplated hereby, and) Tj
0 -12 Td
(no Party hereto shall be bound by or liable for any alleged understanding, promise,) Tj
0 -12 Td
ET
endstream
endobj
12 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 15 0 R >> >> /Contents 11 0 R >>
endobj
13 0 obj
<< /Length 1333 >>
stream
BT
/F1 10 Tf
72 720 Td
(inducement, statement, representation, warranty, covenant or condition not so set forth.) Tj
0 -12 Td
(12.       COUNTERPARTS. This Agreement may be executed in one or more counterparts, each) Tj
0 -12 Td
(of which when executed and delivered shall be an original, and all of which when executed) Tj
0 -12 Td
(shall constitute one and the same instrument.   13.     EXPENSES ASSOCIATED WITH THIS) Tj
0 -12 Td
(AGREEMENT. Marv shall be reimbursed in full for the cost\(s\) of all legal expenses) Tj
0 -12 Td
(associated with this agreement by THI.    [remainder of page intentionally left blank;) Tj
0 -12 Td
(signature page to follow]) Tj
0 -12 Td
() Tj
0 -12 Td
(5) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(IN WITNESS WHEREOF, the Parties hereto, agreeing to be bound hereby, execute this) Tj
0 -12 Td
(Agreement upon the date first set forth above.     Premier Biomedical, Inc.:     /s/) Tj
0 -12 Td
(William Hartman                                Date__________ By: William Hartman, CEO) Tj
0 -12 Td
(Technology Health, Inc.:     /s/ James Christopher LeDoux               Date___________) Tj
0 -12 Td
(By: CEO      Marv Enterprises, LLC:     /s/ Mitchell Felder) Tj
0 -12 Td
(Date__________ By:  Mitchell Felder) Tj
0 -12 Td
() Tj
0 -12 Td
(6) Tj
0 -12 Td
ET
endstream
endobj
14 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 15 0 R >> >> /Contents 13 0 R >>
endobj
15 0 obj
<< /Type /Font /Subtype /Type1 /BaseFont /Helvetica >>
endobj
xref
0 16
0000000000 65535 f 
0000000009 00000 n 
0000000058 00000 n 
0000000150 00000 n 
0000005285 00000 n 
0000005412 00000 n 
0000010703 00000 n 
0000010830 00000 n 
0000016085 00000 n 
0000016212 00000 n 
0000021386 00000 n 
0000021514 00000 n 
0000027182 00000 n 
0000027311 00000 n 
0000028697 00000 n 
0000028826 00000 n 
trailer << /Size 16 /Root 1 0 R >>
startxref
28897
%%EOF
